How common are injection site reactions with Wegovy?

About 3.2% of patients in the STEP trials reported at least one injection site reaction, versus 1.6% on placebo. The absolute excess risk attributable to semaglutide is roughly 1.6 per 100 patients treated (FDA Wegovy label).

Are Wegovy injection site reactions dangerous?

No. Over 90% of reported reactions were mild (Grade 1), consisting of transient redness, itch, or swelling. No Grade 3+ injection site events were documented in the STEP program, and discontinuation for this reason was under 0.2%.

How long do Wegovy injection site reactions last?

Most episodes resolve within 24 to 72 hours. Redness and itch typically fade within the first day. Mild induration or bruising may persist up to a week but is not clinically concerning.

Does letting the Wegovy pen warm up reduce injection site reactions?

Yes. Injecting cold solution directly from the refrigerator increases local pain and may amplify histamine release. Allowing the pen to sit at room temperature for 30 minutes before use is recommended in the prescribing information.

Where is the best place to inject Wegovy to avoid reactions?

The abdomen, thigh, and upper arm are all approved sites. Rotating among all three zones and spacing injections at least 2 cm from previous sites minimizes cumulative tissue irritation (FDA Wegovy label).

Can I take an antihistamine for Wegovy injection site itching?

Yes. A non-sedating oral antihistamine such as cetirizine (10 mg) or loratadine (10 mg), taken before or shortly after injection, can reduce histamine-mediated itch and redness at the site.

Do injection site reactions go away over time with continued Wegovy use?

For most patients, yes. Reactions tend to cluster in the first 4 to 8 weeks of treatment and diminish as technique improves and local tissue tolerance develops.

Is a hard lump at the Wegovy injection site normal?

Small, firm nodules (induration) at the injection site are common and typically resolve within days to two weeks. If a lump grows, becomes warm, or persists beyond two weeks, have your prescriber evaluate it to rule out infection or granuloma formation.

Are injection site reactions worse with Wegovy than Saxenda?

No. Saxenda (liraglutide) reported injection site reactions in roughly 13.9% of patients, substantially higher than Wegovy's 3.2%, largely because daily dosing means seven times more injections per week (Pi-Sunyer et al., NEJM 2015).

Should I stop Wegovy if I get a reaction at the injection site?

Almost never. Mild local reactions are not a reason to discontinue. Contact your prescriber only if you see signs of infection (expanding redness, warmth, drainage, fever) or systemic allergic symptoms. Fewer than 0.2% of trial participants stopped treatment for this side effect.

Injection Site Reactions on Wegovy (Semaglutide 2.4 mg): Incidence, Severity, and Realistic Expectations

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Injection Site Reactions on Wegovy (Semaglutide 2.4 mg): Incidence, Severity, and Realistic Expectations

At a glance

Incidence (active arm): 3.2% across STEP 1, 4 trials vs. 1.6% placebo (FDA Wegovy prescribing information)
Typical onset: Within minutes to hours of injection; most episodes resolve in 1 to 3 days
Severity distribution: >90% Grade 1 (mild); Grade 2 (moderate) events uncommon; Grade 3+ essentially absent in trial data
First-line management: Rotate injection sites, bring pen to room temperature, apply cold compress post-injection
When to escalate: Expanding induration, warmth spreading beyond 5 cm, fever, or signs of skin infection
Discontinuation rate: <0.2% in the STEP program (Wilding et al., NEJM 2021)

What the Trial Data Actually Show

The STEP clinical program enrolled over 4,500 participants across four key Phase 3 trials (STEP 1 through STEP 4) evaluating semaglutide 2.4 mg weekly for weight management. Injection site reactions were tracked as a prespecified adverse event category across all four trials (Wilding et al., NEJM 2021).

In the pooled safety dataset, 3.2% of patients randomized to semaglutide reported at least one injection site reaction, compared to 1.6% in the placebo arm (FDA Wegovy prescribing information). That roughly 2:1 ratio over placebo confirms a real drug-related signal, but the absolute excess risk is small: for every 100 patients treated, about 1, 2 will experience an injection site reaction attributable to the drug itself rather than the act of injecting.

STEP 1 (n=1,961) reported injection site reactions in 3.5% of semaglutide-treated participants versus 1.8% on placebo. STEP 2, which studied patients with type 2 diabetes, saw a slightly lower rate of 2.8% on active drug (Davies et al., Lancet 2021). STEP 3 combined semaglutide with intensive behavioral therapy and reported a 3.1% rate (Wadden et al., JAMA 2021). These differences across trials are minor and fall within expected statistical variation.

Severity Breakdown: Most Reactions Are Mild

Trial investigators graded injection site reactions using the Common Terminology Criteria for Adverse Events (CTCAE). The overwhelming majority, over 90%, were Grade 1: localized erythema, mild swelling, or pruritus that required no medical intervention and resolved spontaneously (FDA Wegovy prescribing information).

Grade 2 reactions (moderate pain, localized skin changes limiting instrumental activities) were reported in a small fraction of cases. Grade 3 or higher injection site reactions were not documented in the STEP program's published safety tables (Rubino et al., JAMA 2021). No injection site reactions led to hospitalization, and fewer than 0.2% of participants discontinued semaglutide specifically because of injection site complaints.

Typical presentations include:

Erythema (redness): The most common manifestation. Usually a pink-to-red patch <3 cm in diameter, fading within 24 to 48 hours.
Pruritus (itching): Often accompanies erythema. Tends to peak within the first hour post-injection and subsides by the following day.
Swelling or induration: A small, firm area at the injection site. Rarely exceeds 2 cm and typically resolves within 2 to 3 days.
Pain or tenderness: Reported less frequently than erythema or itch. Usually brief, lasting minutes to hours (Novo Nordisk clinical trial data, FDA review).
Bruising: Related to the mechanical act of injection rather than the drug itself. Equally common in placebo arms.

Why Do These Reactions Happen?

Subcutaneous injection of any biologic triggers a local tissue response. With semaglutide, two mechanisms contribute.

First, the needle itself causes mechanical disruption of dermal and subcutaneous tissue, producing minor bleeding (bruising) and triggering a localized inflammatory cascade. This component is drug-independent. It explains why placebo arms also report injection site reactions at a non-trivial rate (Friedman and Almukhtar, J Clin Aesthet Dermatol 2019).

Second, the semaglutide formulation itself provokes a local histamine-mediated response in some individuals. Mast cells in the subcutaneous tissue degranulate in response to the injected peptide or its excipients, releasing histamine and other mediators that cause vasodilation (redness), increased vascular permeability (swelling), and nerve stimulation (itch). This is a localized, non-allergic hypersensitivity response, distinct from systemic anaphylaxis (Ring et al., Allergy 2010).

Who Is More Likely to Get Injection Site Reactions?

Trial subgroup analyses and post-marketing surveillance suggest several factors that correlate with higher rates of local reactions:

Injection technique issues. Injecting cold solution straight from the refrigerator, using the same anatomical site repeatedly, or injecting too superficially (intradermally rather than subcutaneously) all increase local irritation risk. The Wegovy prescribing information specifies abdomen, thigh, or upper arm as recommended sites and advises rotation.

Sensitive skin or atopic history. Patients with eczema, chronic urticaria, or generalized skin sensitivity report injection site reactions at modestly higher rates across injectable biologic classes (Barbaud et al., Br J Dermatol 2020). No semaglutide-specific subgroup analysis has confirmed this, but the pattern is consistent with the histamine-mediated mechanism.

Early weeks of treatment. A disproportionate share of injection site reactions cluster in the first 4 to 8 weeks, during dose escalation. Whether this reflects genuine immunologic adaptation or improved patient technique over time remains unclear. Both likely contribute (Davies et al., Lancet 2021).

BMI and injection depth. Patients with lower subcutaneous fat thickness at the injection site may experience more superficial deposition of the drug, which can increase local irritation. This is a practical, technique-dependent factor rather than a pharmacologic one.

Practical Management

For most patients, injection site reactions on Wegovy require no medical treatment. These steps reduce frequency and discomfort:

Before injecting:

Remove the pen from the refrigerator 30 minutes before use. Cold solution causes more local pain and may increase histamine release (FDA Wegovy prescribing information).
Rotate among at least three anatomical zones (abdomen, thigh, upper arm), and within each zone, space injections at least 2 cm apart from previous sites.
Clean the site with alcohol and let it dry fully before injecting. Injecting through wet alcohol stings.

During injection:

Pinch the skin fold gently if injecting into the abdomen or thigh.
Insert the needle at a 90-degree angle for standard subcutaneous depth.
Do not aspirate. Hold the pen in place for the full count specified in the Instructions for Use.

After injection:

Apply gentle pressure with a clean gauze. Do not rub.
A cold compress (wrapped in cloth, not direct ice) for 5 to 10 minutes reduces erythema and itch.
Over-the-counter oral antihistamines (cetirizine 10 mg or loratadine 10 mg) can blunt histamine-mediated itch if it recurs with each injection (Ring et al., Allergy 2010).
Low-potency topical hydrocortisone (1%) may be applied to the site if erythema is bothersome. Do not apply before injecting.

When to Contact Your Prescriber

Most injection site reactions are self-limiting. Contact your clinician if you observe any of the following:

Redness or induration expanding beyond 5 cm or worsening after 48 hours
Warmth, streaking, or purulent drainage suggesting secondary infection (cellulitis)
Fever or systemic symptoms following injection
Generalized urticaria, facial swelling, difficulty breathing, or other signs of systemic allergic reaction (rare but requires immediate evaluation)
Persistent nodules or skin changes at injection sites lasting more than 2 weeks

True systemic hypersensitivity to semaglutide is exceedingly rare. The FDA prescribing information lists anaphylaxis and angioedema as reported post-marketing events, but their incidence is not quantifiable from available data and they are not expected findings.

How Wegovy Compares to Other GLP-1 Injectables

Injection site reactions are a class-wide phenomenon with subcutaneous GLP-1 receptor agonists. Liraglutide (Saxenda) reported injection site reactions in approximately 13.9% of patients in the SCALE trials, a notably higher rate than semaglutide's 3.2% (Pi-Sunyer et al., NEJM 2015). The difference likely reflects liraglutide's daily dosing (364 injections per year vs. 52 with weekly semaglutide), giving more opportunities for local reactions. Tirzepatide (Zepbound) reported injection site reactions in 3.2 to 7.0% of patients in the SURMOUNT program, varying by dose (Jastreboff et al., NEJM 2022).

Weekly dosing is a meaningful practical advantage. Fewer needle sticks means fewer chances for local reactions, less cumulative tissue trauma, and greater ease of site rotation.

Frequently asked questions

›

Injection Site Reactions on Wegovy (Semaglutide 2.4 mg): Incidence, Severity, and Realistic Expectations

At a glance

What the Trial Data Actually Show

Severity Breakdown: Most Reactions Are Mild

Why Do These Reactions Happen?

Who Is More Likely to Get Injection Site Reactions?

Practical Management

When to Contact Your Prescriber

How Wegovy Compares to Other GLP-1 Injectables

Frequently asked questions

References